Mac-2 binding protein glycosylation isomer predicts tolerability and clinical outcome of lenvatinib therapy for hepatocellular carcinoma.

Yuji EsoShigeharu NakanoMasako MishimaSoichi ArasawaEriko IguchiHaruhiko TakedaAtsushi TakaiKen TakahashiKojiro TauraHiroshi Seno

Published in: Journal of hepato-biliary-pancreatic sciences (2021)

Baseline M2BPGi levels may predict the tolerability and treatment response to lenvatinib. Patients with high M2BPGi levels may less likely to benefit from lenvatinib therapy.

Keyphrases

binding protein
open label
stem cells
double blind
bone marrow
replacement therapy
cell therapy
study protocol